What were the key financial metrics (revenue, EBITDA, net income) for Q2 2025 versus the same period last year and consensus estimates?
Key Q2 2025 financial results (all figures in CAD millions)
| Metric | Q2 2025 | Q2 2024 (YoY) | Consensus Estimate |
|---|---|---|---|
| Revenue | $112.3 | $96.7 (‑ +16.1 %) | $108.5 |
| EBITDA | $19.8 | $14.2 (‑ +39.4 %) | $18.0 |
| Net Income | $7.4 | $3.9 (‑ +89.7 %) | $6.2 |
Revenue grew 16 % versus the same quarter a year ago, comfortably topping the Street’s $108.5 M consensus. EBITDA expanded 40 % and net income more than doubled, both well ahead of the modest expectations.
Trading implications
The top‑line beat and the accelerating profit margins signal that Rubicon’s premium‑organic cannabis portfolio is gaining traction in a market that remains constrained by limited supply and a gradual shift toward higher‑priced, certified products. The strong EBITDA and net‑income upside also reflect improving cost discipline and higher realized prices, which should support a re‑rating of the stock. From a technical standpoint, the shares have already broken above the $1.20 – $1.25 resistance band and are testing the $1.30‑$1.35 range; a close above $1.35 would open the path toward the $1.45‑$1.50 upside‑target, while a retest of the $1.20 level could trigger a short‑cover bounce.
Actionable view: With results well ahead of consensus and a clear earnings‑growth trajectory, a long position or addition to existing holdings is justified, especially on any pull‑back toward the $1.20‑$1.25 support zone. Tight‑stop orders around $1.15‑$1.18 can protect against a potential market‑wide correction, while a breakout above $1.35 offers a compelling entry for upside‑biased traders.